Ascendis Pharma A/S Q2 2021 Earnings Call Transcript - Thomson StreetEvents

Ascendis Pharma A/S Q2 2021 Earnings Call Transcript

Ascendis Pharma A/S Q2 2021 Earnings Call Transcript - Thomson StreetEvents
Ascendis Pharma A/S Q2 2021 Earnings Call Transcript
Published Aug 25, 2021
Published Aug 25, 2021
Price US$ 54.00  |  Buy this Report Now

About This Report

  
Abstract:

Edited Transcript of ASND.OQ earnings conference call or presentation 25-Aug-21 8:30pm GMT

  
Report Type:

Transcript

Source:
Thomson StreetEvents
Company:
Ascendis Pharma A/S
Ticker
ASND.OQ
Time
8:30pm GMT
Format:
PDF Adobe Acrobat
Buy Now

The following is excerpted from the question-and-answer section of the transcript.

(Questions from industry analysts are provided in full, but answers are omitted - download the transcript to see the full question-and-answer session)

Question: Jessica Macomber Fye - JPMorgan Chase & Co, Research Division - Analyst : Congrats on the approval. A couple from me. First, can you please explain which part of the data investors should look to in the label that reflects the superiority of SKYTROFA's efficacy over GENOTROPIN? Is it the lower bound of the 95% confidence interval in Table 4 of the clinical study section?

Question: Jessica Macomber Fye - JPMorgan Chase & Co, Research Division - Analyst : Okay. How does this timing of approval impact your payer conversations, if at all? Is it possible you can catch the late summer window for coverage discussions? And what's the list price per milligram going to be?

Question: Michelle Lim Gilson - Canaccord Genuity Corp., Research Division - Analyst : Congratulations. I'm also a very happy Michelle. I noticed the label. It looks very, very similar to daily growth hormone. I guess just with this in mind, do you think physicians will see SKYTROFA as interchangeable with daily growth hormone in the way that the labels are in? And do you anticipate there will be any pull-through demand beyond the initial indication into the other growth hormone approved indications?

Question: Michelle Lim Gilson - Canaccord Genuity Corp., Research Division - Analyst : And if I can also add a follow-up, how do you plan to communicate SKYTROFA's differentiation from other long-acting growth hormones if they are approved in the future? I know you mentioned the immunogenic profile in your prepared remarks.

Question: Anita Dushyanth - Joh. Berenberg, Gossler & Co. KG, Research Division - Analyst : Congratulations on the approval. So I guess -- or maybe you could help me understand this a little bit. I know you mentioned earlier that it's going to take some time for the drug to get on the formulary. So are you kind of providing some kind of support to accelerate the prior authorizations to provide accelerated patient access? And then I just wanted to know, regarding your application in the European region, are you still expecting approval in Q4?

Table Of Contents

Ascendis Pharma A/S Q4 2021 Earnings Call Transcript – 2022-03-02 – US$ 54.00 – Edited Transcript of ASND.OQ earnings conference call or presentation 2-Mar-22 9:30pm GMT

Ascendis Pharma A/S at JPMorgan Healthcare Conference (Virtual) Transcript – 2022-01-10 – US$ 54.00 – Edited Transcript of ASND.OQ presentation 10-Jan-22 8:00pm GMT

Ascendis Pharma A/S R&D Update Transcript – 2021-12-14 – US$ 54.00 – Edited Transcript of ASND.OQ conference call or presentation 14-Dec-21 2:00pm GMT

Ascendis Pharma A/S Q3 2021 Earnings Call Transcript – 2021-11-10 – US$ 54.00 – Edited Transcript of ASND.OQ earnings conference call or presentation 10-Nov-21 9:30pm GMT

Ascendis Pharma A/S at Morgan Stanley Global Healthcare Conference (Virtual) Transcript – 2021-09-15 – US$ 54.00 – Edited Transcript of ASND.OQ presentation 15-Sep-21 4:30pm GMT

Ascendis Pharma A/S Q1 2021 Earnings Call Transcript – 2021-05-27 – US$ 54.00 – Edited Transcript of ASND.OQ earnings conference call or presentation 27-May-21 8:30pm GMT

Ascendis Pharma A/S Presents At Bank of America Securities 2021 Healthcare Conference (Virtual) Transcript – 2021-05-11 – US$ 54.00 – Edited Transcript of ASND.OQ presentation 11-May-21 8:15pm GMT

Full Year 2020 Ascendis Pharma A/S Earnings Call Transcript – 2021-03-10 – US$ 54.00 – Edited Transcript of ASND.OQ earnings conference call or presentation 10-Mar-21 9:30pm GMT

Ascendis Pharma A/S at SVB Leerink Global Healthcare Conference (Virtual) Transcript – 2021-02-24 – US$ 54.00 – Edited Transcript of ASND.OQ presentation 24-Feb-21 8:40pm GMT

Ascendis Pharma A/S at JPMorgan Healthcare Conference (Virtual) Transcript – 2021-01-11 – US$ 54.00 – Edited Transcript of ASND.OQ presentation 11-Jan-21 4:40pm GMT

More from Thomson StreetEvents

Thomson StreetEvents—Thomson StreetEvents is a leading provider of Web-based solutions for the investment community, offering services that transform the way companies communicate and meet disclosure requirements while assisting investors in managing and leveraging this information. Thomson StreetEvents service offers institutional investors a one-stop solution for managing corporate disclosure information by aggregating conference calls, webcasts, transcripts, call summaries, and other financial information into a time-saving, efficiency tool.
Purchase Thomson StreetEvents' Transcripts (verbatim reports) and Briefs (call summaries) of earnings, guidance, M&A and other corporate calls directly through Alacra. Discounted prices apply to reports produced over two weeks ago.

About the Author


Cite this Report

  
MLA:
Thomson StreetEvents. "Ascendis Pharma A/S Q2 2021 Earnings Call Transcript" Aug 25, 2021. Alacra Store. May 04, 2025. <http://www.alacrastore.com/thomson-streetevents-transcripts/Q2-2021-Ascendis-Pharma-A-S-Earnings-Call-T14966924>
  
APA:
Thomson StreetEvents. (2021). Ascendis Pharma A/S Q2 2021 Earnings Call Transcript Aug 25, 2021. New York, NY: Alacra Store. Retrieved May 04, 2025 from <http://www.alacrastore.com/thomson-streetevents-transcripts/Q2-2021-Ascendis-Pharma-A-S-Earnings-Call-T14966924>
  
US$ 54.00
$  £  €
Have a Question?

Any questions about the report you're considering? Our Customer Service Team can help! Or visit our FAQs.

More Research

Search all our Credit Research from one place.